Condition: Advanced Hepatocellular Carcinoma (HCC) · Sponsor: Zhejiang Haichang Biotech Co., Ltd.
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
This description comes directly from the study's public registry record.
Angela Men, MD., Ph.D · +1 2407020080 · angela.men@thewogroup.com
Always discuss trial participation with your own doctor first.
| China Pharmaceutical University, Shanghai Gobroad Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital Sichuan University | Chengdu, China | Recruiting |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Prince of Wales Hospital | Hong Kong, Hong Kong | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06309485